IL6 and cancer: Although Elsilimomab (BE-8) did not show clinical efficacy in cancer patients, other anti-IL-6 mAbs such as mAb 1339 (OP-R003) and ALD518/BMS-945429 have exhibited potential anti-tumor activity in vivo, inducing significant clinical response in patients with different disorders [252], suggesting that they could be used to treat cancer.